Anticipating Phase 3 discussions with FDA Division of Neurology in Q3 2017. I don't think this limits partnering, as I would expect partners paying for P3 would want a say in trial design.
Disappointingly no mention of where they are at re: deal discussions. I am sure this is quite intentional, but I think the missing thing for us all.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.56 |
Change
0.080(0.49%) |
Mkt cap ! $2.093B | |||
| Open | High | Low | Value | Volume |
| $16.48 | $16.77 | $16.28 | $2.042M | 123.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 149 | $16.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.57 | 56 | 4 |
View Market Depth
| Last trade - 14.23pm 28/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |